Our understanding of (axSpA) has really changed, especially with regard to male-female differences. In this report, we identify important research on axSpA presented at ACR Convergence 2024, summarize the abstracts and comment on why each is important, addressing the relevance for clinicians and the potential impact on future research.
Experts offered perspectives on how symptoms of rheumatic disease, such as fatigue, affect the physical, cognitive and emotional health of patients and offered solutions.
In an effort to ameliorate serious rheumatology provider shortages, the ACR Workforce Solutions Committee has developed a new resource for primary care providers who treat patients with rheumatic conditions.
Burmester et al. characterized the long-term safety profile of upadacitinib treatment across multiple rheumatic diseases.
Two studies outline the roles of air pollution and T cell imbalance in the pathogenesis of systemic lupus erythematosus.
Upadacitinib, as a tablet and oral solution, is now FDA approved to treat children age 2 years and older with active polyarticular juvenile idiopathic arthritis or psoriatic arthritis.
Dr. Maria Tektonidou discussed the latest recommendations for the treatment of patients with antiphospholipid syndrome (APS), including obstetric and thrombotic subtypes.
Although research is still emerging, evidence suggests changes in climate, such as increases in heat, pollution and allergens, may increase the risk of flare and hospitalization in patients with rheumatoid arthritis, systemic lupus erythematosus and other rheumatic conditions. Paul Dellaripa, MD, discussed the research and how rheumatologists can help their patients.
Dr. Jens Thiel provided a detailed overview of specific treatments for patients with immunoglobulin A (IgA) vasculitis and IgA nephropathy, highlighting treatments in early clinical trials.
Background & Objectives The ORAL Surveillance trial (NCT02092467), a postauthorization safety study of tofacitinib in patients with rheumatoid arthritis (RA) aged 50 years or older with at least one additional cardiovascular risk factor, found a dose-dependent increase in venous thromboembolism (VTE) and pulmonary embolism (PE) events when patients were treated with tofacitinib vs. a tumor…